516 related articles for article (PubMed ID: 18041833)
1. Structure-guided design of AMP mimics that inhibit fructose-1,6-bisphosphatase with high affinity and specificity.
Erion MD; Dang Q; Reddy MR; Kasibhatla SR; Huang J; Lipscomb WN; van Poelje PD
J Am Chem Soc; 2007 Dec; 129(50):15480-90. PubMed ID: 18041833
[TBL] [Abstract][Full Text] [Related]
2. Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.
Dang Q; Kasibhatla SR; Reddy KR; Jiang T; Reddy MR; Potter SC; Fujitaki JM; van Poelje PD; Huang J; Lipscomb WN; Erion MD
J Am Chem Soc; 2007 Dec; 129(50):15491-502. PubMed ID: 18041834
[TBL] [Abstract][Full Text] [Related]
3. Fructose-1,6-bisphosphatase inhibitors. 1. Purine phosphonic acids as novel AMP mimics.
Dang Q; Brown BS; Liu Y; Rydzewski RM; Robinson ED; van Poelje PD; Reddy MR; Erion MD
J Med Chem; 2009 May; 52(9):2880-98. PubMed ID: 19348494
[TBL] [Abstract][Full Text] [Related]
4. Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.
Dang Q; Kasibhatla SR; Xiao W; Liu Y; Dare J; Taplin F; Reddy KR; Scarlato GR; Gibson T; van Poelje PD; Potter SC; Erion MD
J Med Chem; 2010 Jan; 53(1):441-51. PubMed ID: 20055427
[TBL] [Abstract][Full Text] [Related]
5. Calculation of relative binding affinities of fructose 1,6-bisphosphatase mutants with adenosine monophosphate using free energy perturbation method.
Mutyala R; Reddy RN; Sumakanth M; Reddanna P; Reddy MR
J Comput Chem; 2007 Apr; 28(5):932-7. PubMed ID: 17253638
[TBL] [Abstract][Full Text] [Related]
6. [Recent advance in the discovery of allosteric inhibitors binding to the AMP site of fructose-1,6-bisphosphatase].
Li ZM; Bie JB; Song HR; Xu BL
Yao Xue Xue Bao; 2011 Nov; 46(11):1291-300. PubMed ID: 22260018
[TBL] [Abstract][Full Text] [Related]
7. Allosteric FBPase inhibitors gain 10(5) times in potency when simultaneously binding two neighboring AMP sites.
Hebeisen P; Kuhn B; Kohler P; Gubler M; Huber W; Kitas E; Schott B; Benz J; Joseph C; Ruf A
Bioorg Med Chem Lett; 2008 Aug; 18(16):4708-12. PubMed ID: 18650089
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, SAR, and X-ray structure of tricyclic compounds as potent FBPase inhibitors.
Tsukada T; Takahashi M; Takemoto T; Kanno O; Yamane T; Kawamura S; Nishi T
Bioorg Med Chem Lett; 2009 Oct; 19(20):5909-12. PubMed ID: 19762234
[TBL] [Abstract][Full Text] [Related]
9. MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes.
Erion MD; van Poelje PD; Dang Q; Kasibhatla SR; Potter SC; Reddy MR; Reddy KR; Jiang T; Lipscomb WN
Proc Natl Acad Sci U S A; 2005 May; 102(22):7970-5. PubMed ID: 15911772
[TBL] [Abstract][Full Text] [Related]
10. Interaction between muscle aldolase and muscle fructose 1,6-bisphosphatase results in the substrate channeling.
Rakus D; Pasek M; Krotkiewski H; Dzugaj A
Biochemistry; 2004 Nov; 43(47):14948-57. PubMed ID: 15554702
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the allosteric binding pocket of human liver fructose-1,6-bisphosphatase by protein crystallography and inhibitor activity studies.
Iversen LF; Brzozowski M; Hastrup S; Hubbard R; Kastrup JS; Larsen IK; Naerum L; Nørskov-Lauridsen L; Rasmussen PB; Thim L; Wiberg FC; Lundgren K
Protein Sci; 1997 May; 6(5):971-82. PubMed ID: 9144768
[TBL] [Abstract][Full Text] [Related]
12. Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in type 2 diabetes.
van Poelje PD; Potter SC; Erion MD
Handb Exp Pharmacol; 2011; (203):279-301. PubMed ID: 21484576
[TBL] [Abstract][Full Text] [Related]
13. Different sensitivities of mutants and chimeric forms of human muscle and liver fructose-1,6-bisphosphatases towards AMP.
Rakus D; Tillmann H; Wysocki R; Ulaszewski S; Eschrich K; Dzugaj A
Biol Chem; 2003 Jan; 384(1):51-8. PubMed ID: 12674499
[TBL] [Abstract][Full Text] [Related]
14. Crystal structures of the active site mutant (Arg-243-->Ala) in the T and R allosteric states of pig kidney fructose-1,6-bisphosphatase expressed in Escherichia coli.
Stec B; Abraham R; Giroux E; Kantrowitz ER
Protein Sci; 1996 Aug; 5(8):1541-53. PubMed ID: 8844845
[TBL] [Abstract][Full Text] [Related]
15. A study of subunit interface residues of fructose-1,6-bisphosphatase by site-directed mutagenesis: effects on AMP and Mg2+ affinities.
Shyur LF; Aleshin AE; Fromm HJ
Biochemistry; 1996 Jun; 35(23):7492-8. PubMed ID: 8652527
[TBL] [Abstract][Full Text] [Related]
16. Evidence for an active T-state pig kidney fructose 1,6-bisphosphatase: interface residue Lys-42 is important for allosteric inhibition and AMP cooperativity.
Lu G; Stec B; Giroux EL; Kantrowitz ER
Protein Sci; 1996 Nov; 5(11):2333-42. PubMed ID: 8931152
[TBL] [Abstract][Full Text] [Related]
17. Evolutionary conserved N-terminal region of human muscle fructose 1,6-bisphosphatase regulates its activity and the interaction with aldolase.
Gizak A; Maciaszczyk E; Dzugaj A; Eschrich K; Rakus D
Proteins; 2008 Jul; 72(1):209-16. PubMed ID: 18214967
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel indole derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase.
Bie J; Liu S; Li Z; Mu Y; Xu B; Shen Z
Eur J Med Chem; 2015 Jan; 90():394-405. PubMed ID: 25461330
[TBL] [Abstract][Full Text] [Related]
19. Kinetic properties of Pelophylax esculentus muscle FBPase.
Dziewulska-Szwajkowska D; Dzugaj A
Comp Biochem Physiol B Biochem Mol Biol; 2010 Nov; 157(3):294-300. PubMed ID: 20656052
[TBL] [Abstract][Full Text] [Related]
20. Structure of inhibited fructose-1,6-bisphosphatase from Escherichia coli: distinct allosteric inhibition sites for AMP and glucose 6-phosphate and the characterization of a gluconeogenic switch.
Hines JK; Kruesel CE; Fromm HJ; Honzatko RB
J Biol Chem; 2007 Aug; 282(34):24697-706. PubMed ID: 17567577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
